Clinical trials: Stage II Breast Carcinoma
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast Cancer
This study evaluates pre-analytical factors affecting circulating tumor deoxyribonucleic acid (ctDNA) analysis in breast cancer that not spread beyond the breast and or lymph nodes (early and locally advanced).
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Breast Carcinoma
- Trial name
- NCT05945290
- Testing
- Biospecimen Collection, Electronic Health Record Review
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Mayo Clinic
Adult Solid Tumor, Adenocarcinoma of the Colon
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
RATIONALE: PD 0332991 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well PD 0332991 works in treating patients with…
- Conditions
- Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor
- Trial name
- NCT01037790
- Testing
- PD-0332991
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA)
This is a single arm, open-label, lead in phase Ib dose confirmation, followed by phase II study with 2 parallel study cohorts.
- Trial name
- NCT04280536
- Testing
- Cohort A, Cohort B
- Where
- Singapore
- Volunteers
- 86 people
- Sponsor
- National University Hospital, Singapore
Breast Cancer, Colorectal Cancer
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Vaccines made from a person's white blood cells that have been treated in the laboratory may make the body build an immune response to kill tumor cells.
- Conditions
- Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer
- Trial name
- NCT00027534
- Testing
- TRICOM-CEA(6D)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Michael Morse, MD
HER2-negative Breast Cancer, Advanced Solid Tumor
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
This is an open label, lead in phase Ib dose confirmation study in patients with advanced solid tumors, followed by a phase II single arm study as neoadjuvant therapy in stage I-III HER2 negative breast cancer.
- Trial name
- NCT05275777
- Testing
- ADG106, Doxorubicin, Cyclophosphamide
- Where
- Singapore
- Volunteers
- 66 people
- Sponsor
- National University Hospital, Singapore
Breast Cancer
APBI: 27Gy in 5 Fractions for Early Breast Cancer
This study will test the safety of partial breast RT using 27Gy in 5 daily fractions which is expected to be equally tolerated as standard whole breast irradiation (WBI) based on radiobiologic modeling of the fibrosis response of…
- Trial name
- ACCEL (NCT02681107)
- Testing
- APBI 27Gy in 5 fractions
- Where
- Canada
- Volunteers
- 274 people
- Sponsor
- AHS Cancer Control Alberta
Breast Cancer
Partial Breast Irradiation With Chemotherapy
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells…
- Trial name
- NCT00278109
- Testing
- cyclophosphamide, Doxorubicin, radiation
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, Estrogen Receptor-positive Breast Cancer
Pre-operative Immunotherapy Combination Strategies in Breast Cancer
International, open label, window of opportunity phase II trial that aims to evaluate the effects of immunotherapy based treatment combinations in women with untreated, histologically confirmed, operable, ER+, HER2-negative…
- Trial name
- ECLIPSE (NCT03395899)
- Testing
- Atezolizumab, Cobimetinib, Ipatasertib
- Where
- United Kingdom
- Volunteers
- 71 people
- Sponsor
- Queen Mary University of London
Breast Cancer
Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
RATIONALE: Dose-dense scheduling with (peg)filgrastim support may improve the clinical and pathologic complete response rate (pCR) and safety profile of single agent neoadjuvant docetaxel therapy.
- Trial name
- NCT00343512
- Testing
- docetaxel, protein expression analysis, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Solid Tumor, Adult
Study of DF1001 in Patients With Advanced Solid Tumors
DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases.
- Trial name
- NCT04143711
- Testing
- DF1001, Nivolumab, Nab paclitaxel
- Where
- 44 sites in United States, Belgium and 4 more
- Volunteers
- 270 people
- Sponsor
- Dragonfly Therapeutics
Advanced Breast Cancer
First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer
This phase II study focuses on women with rapidly progressive hormone receptor-positive and HER2-negative advanced breast cancer, including patients with symptomatic visceral metastases, rapidly increasing tumor burden, impending…
- Trial name
- NCT06375707
- Testing
- Ribociclib
- Where
- China
- Volunteers
- 74 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Recurrent Breast Cancer, Stage IIIB Breast Cancer
Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer
This phase I/II trial studies the best dose of suramin when given together with paclitaxel in treating women with stage IIIB-IV breast cancer.
- Conditions
- Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00054028
- Testing
- suramin, paclitaxel, pharmacological study
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
In this trial we will evaluate ABI-007 with gemcitabine and epirubicin, utilizing the biweekly pegfilgrastim support, in order to further improve upon the effectiveness and favorable toxicity of this triplet.
- Trial name
- NCT00193206
- Testing
- Gemcitabine, Epirubicin, Albumin-bound Paclitaxel
- Where
- 13 sites in United States
- Volunteers
- 123 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer Metastatic
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
This is a randomized, open-label, multi-center, Phase II clinical study to evaluate the efficacy and safety of margetuximab plus chemotherapy compared with trastuzumab plus chemotherapy in Chinese patients (Mainland, Hong Kong…
- Trial name
- NCT04262804
- Testing
- Margetuximab, Trastuzumab, Chosen Chemotherapy (Capecitabine)
- Where
- Taiwan
- Volunteers
- 123 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Breast Neoplasms
An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer
The purpose of this study is to evaluate the effectiveness and safety of trabectedin in 3 subpopulations of participants with previously treated progressive metastatic ( spread of a cancer from one organ or part to another…
- Trial name
- NCT00580112
- Testing
- Dexamethasone, Trabectedin
- Where
- 33 sites in United States, France and 2 more
- Volunteers
- 127 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
TNBC, Adjuvant Therapy
A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.
This study is a prospective, multicenter, phase II clinical trial designed to evaluate the efficacy and safety of postoperative chemotherapy combined with QL1706 in patients with high-risk triple-negative breast cancer.
- Conditions
- TNBC, Adjuvant Therapy, Lymph Node Positive
- Trial name
- NCT07622836
- Testing
- Aipaluoli-tovorilimab plus AC-T chemotherapy as postoperative adjuvant therapy
- Where
- China
- Volunteers
- 59 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Recurrent Breast Carcinoma, Stage IIIB Breast Cancer
Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with breast cancer cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment.
- Conditions
- Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01277757
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases
RATIONALE: Surgery to remove lymph nodes in the armpit in patients with sentinel lymph node micrometastases may remove cancer cells that have spread from tumors in the breast.
- Trial name
- 23-01 (NCT00072293)
- Testing
- Axillary lymph node dissection, No axillary lymph node dissection
- Where
- 31 sites in Australia, Belgium and 8 more
- Volunteers
- 931 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating women who have advanced or…
- Trial name
- NCT00006121
- Testing
- oxaliplatin
- Where
- 10 sites in Austria, Belgium and 5 more
- Volunteers
- 18 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
This phase II trial studies how well atezolizumab, cobimetinib, and eribulin work in treating patients with inflammatory breast cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT03202316
- Testing
- Atezolizumab, Cobimetinib, Eribulin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.